Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Psoriatic Arthritis"

Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 20, 2018

In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…

Identifying Cardiovascular Risk Factors in Psoriatic Arthritis

Larry Beresford  |  November 19, 2018

Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardio­vascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…

Nivolumab-Induced Arthritis

Catherine Strahle, DO, Nathalie E. Chalhoub, MD, & Avis Ware, MD  |  October 18, 2018

Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

Samantha C. Shapiro, MD; Jemima Albayda, MD; & Ana-Maria Orbai, MD, MHS  |  September 20, 2018

A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2018

New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…

Long-Term Apremilast Promising for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2018

In a long-term study, apremilast was well tolerated by patients with psoriatic arthritis, who showed sustained improvements for up to five years…

Study Results for 9 New Psoriatic Arthritis Drugs

Thomas R. Collins  |  June 21, 2018

CHICAGO—As Eric Ruderman, MD, professor of medicine in rheumatology at Northwestern University Feinberg School of Medicine in Chicago, began his talk on psoriatic arthritis treatment at the ACR State-of-the-Art Clinical Symposium in April, he marveled a bit at how much there was to cover. Drugs gaining prominence in the treatment of rheumatoid arthritis and dermatological…

Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study

Michele B. Kaufman, PharmD, BCGP  |  April 26, 2018

Initial results from an ongoing trial show that upadacitinib outperforms adalimumab in achieving ACR20 in patients with rheumatoid arthritis…

EU Approves Marketing for Ixekizumab in Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 7, 2018

In its second indication in the EU, ixekizumab has been approved by the European Commission to treat adults with active psoriatic arthritis…

Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

Michele B. Kaufman, PharmD, BCGP  |  January 31, 2018

The FDA has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis…

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences